Search results
Showing 51 to 100 of 163 results for metastatic breast cancer
In development [GID-TA11402] Expected publication date: TBC
In development [GID-TA11514] Expected publication date: TBC
Spinal metastases and metastatic spinal cord compression (NG234)
This guideline covers recognition, referral, investigation and management of spinal metastases and metastatic spinal cord compression (MSCC). It is also relevant for direct malignant infiltration of the spine and associated cord compression. It aims to improve early diagnosis and treatment to prevent neurological injury and improve prognosis.
Awaiting development [GID-TA11342] Expected publication date: TBC
Awaiting development [GID-TA11273] Expected publication date: TBC
Awaiting development [GID-TA11519] Expected publication date: TBC
Awaiting development [GID-TA11231] Expected publication date: TBC
Entrectinib for treating NTRK fusion-positive solid tumours (TA644)
Evidence-based recommendations on entrectinib (Rozlytrek) for treating neurotrophic tyrosine receptor kinase (NTRK) fusion-positive solid tumours in adults and children over 12 years.
Olaparib with abiraterone for untreated hormone-relapsed metastatic prostate cancer (TA951)
Evidence-based recommendations on olaparib (Lynparza) with abiraterone for untreated hormone-relapsed metastatic prostate cancer in adults.
Breast cancer (locally advanced or metastatic) - ixabepilone [ID377]
Discontinued [GID-TAG403]
Tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancer (DG34)
Evidence-based recommendations on tumour profiling tests to guide adjuvant chemotherapy decisions for people with early breast cancer. The tests are EndoPredict
Intrabeam radiotherapy system for adjuvant treatment of early breast cancer (TA501)
Evidence-based recommendations on using Intrabeam radiotherapy during breast-conserving surgery in adults.
Awaiting development [GID-TA11339] Expected publication date: TBC
Find out about the progress made by the health and care system in implementing NICE guidance on prostate cancer
In development [GID-NG10415] Expected publication date: TBC
This webpage covers NICE guidelines on breast cancer. The table below presents the guidelines alphabetically with links to...
Evidence-based recommendations on dabrafenib (Tafinlar) with trametinib (Mekinist) for resected stage III, BRAF V600 mutation-positive melanoma in adults.
In development [GID-NG10419] Expected publication date: 31 March 2025
Caris Molecular Intelligence for guiding cancer treatment (MIB120)
NICE has developed a medtech innovation briefing (MIB) on Caris Molecular Intelligence for guiding cancer treatment .
Topotecan for the treatment of recurrent and stage IVB cervical cancer (TA183)
Evidence-based recommendations on topotecan for treating recurrent and stage IVB cervical cancer in adults.
Capivasertib with paclitaxel for untreated metastatic triple-negative breast cancer [ID6383]
Awaiting development [GID-TA11411] Expected publication date: TBC
This guideline covers diagnosis and management of thyroid cancer in people aged 16 and over. It aims to reduce variation in practice and increase the quality of care and survival for people with thyroid cancer.
Bone loss (therapy-induced) in non-metastatic breast cancer - denosumab [ID83]
Discontinued [GID-TAG411]
in combination with capecitabine for the first-line treatment of metastatic breast cancer Number TA263 Date issued August 2012
Breast cancer (metastatic) -trastuzumab (as monotherapy and in combination with a taxane) [ID345]
Discontinued [GID-TAG417]
Bevacizumab in combination with a taxane for the first-line treatment of metastatic breast cancer Number TA214 Date issued February 2011
metastases in breast cancer August 2013 DG8 Review decision DG9 EGFR‑TK mutation testing in adults with locally advanced or...
Larotrectinib for treating NTRK fusion-positive solid tumours (TA630)
Evidence-based recommendations on larotrectinib (Vitrakvi) for treating neurotrophic tyrosine receptor kinase (NTRK) fusion-positive solid tumours in adults and children.
Evidence-based recommendations on lymphovenous anastomosis during axillary or inguinal node dissection for preventing secondary lymphoedema in adults. This involves diverting some of the lymphatic vessels around where lymph nodes have been removed to nearby veins.
View recommendations for IPG785Show all sections
This guideline covers care for people with a family history of breast, ovarian or another related (prostate or pancreatic) cancer. It aims to improve the long-term health of these families by describing strategies to reduce the risk of and promote early detection of breast cancer (including genetic testing and mammography). It also includes advice on treatments (tamoxifen, raloxifene) and surgery (mastectomy).
Microwave ablation for primary or metastatic cancer in the lung (IPG716)
Evidence-based recommendations on microwave ablation for primary or metastatic cancer in the lung in adults. This involves inserting a probe into the lung, through the skin of the chest, to send microwaves into the cancer cells. This produces heat, aiming to destroy the cancer (ablation).
View recommendations for IPG716Show all sections
Awaiting development [GID-TA11535] Expected publication date: TBC
Pembrolizumab for previously treated metastatic triple negative breast cancer [ID1246]
Discontinued [GID-TA10295]
NICE has developed a medtech innovation briefing (MIB) on OSNA for colon cancer staging
This guideline covers the diagnosis and management of menopause, including in women who have premature ovarian insufficiency. The guideline aims to improve the consistency of support and information provided to women in menopause.
Irreversible electroporation for treating primary lung cancer and metastases in the lung (IPG441)
Evidence-based recommendations on irreversible electroporation for treating primary lung cancer and metastases in the lung. This involves using electrical pulses to kill cancer cells.
View recommendations for IPG441Show all sections
Sections for IPG441
Prevention of chemotherapy induced nausea and vomiting in adults: netupitant/palonosetron (ESNM69)
Summary of the evidence on netupitant/palonosetron to prevent chemotherapy induced nausea and vomiting to inform local NHS planning and decision-making
Evidence-based recommendations on SonoVue (sulphur hexafluoride microbubbles) for contrast-enhanced ultrasound imaging of the liver
NICE has developed a medtech innovation briefing (MIB) on AlignRT for intracranial stereotactic radiosurgery .
bisphosphonate therapy:- Which groups of people with early and locally advanced breast cancer would benefit...
Bevacizumab for the first-line treatment of metastatic breast cancer (TA147)
This appraisal has been updated and replaced by NICE technology appraisal 214.
increased risk of colorectal cancer:- How effective are colonoscopic surveillance programmes in improving overall survival and...
Eribulin for the treatment of locally advanced or metastatic breast cancer (TA250)
This guidance has been updated and replaced by NICE technology appraisal guidance 423 and NICE technology appraisal guidance 515.